41 completed, 10 terminated, 5 recruiting, 3 withdrawn. 28 Phase 2, 22 Phase 1, 13 Phase 3.
Follow fostamatinib: new trials by email Literature Review of fostamatinib trials Research Report on fostamatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies fostamatinib, Placebo - Lung Transplantation | Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 30 | 2026-10-27 | 2026-10-22 |
| Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults Placebo, Fostamatinib - Acute Respiratory Distress Syndrome, ARDS | Phase 2 | Not yet recruiting | Inova Health Care Services | 40 | 2026-08-30 | 2026-02-02 |
| Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Withdrawn | National Heart, Lung, and Blood Institute (NHLBI) | 2025-11-07 | 2025-11-10 | |
| Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD Fostamatinib, Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Recruiting | Stefanie Sarantopoulos, MD, PhD. | 30 | 2025-10-29 | 2026-01-22 |
| Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease Fostamatinib - Sickle Cell Disorders, Sickle Cell Disease | Phase 1 | Recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 35 | 2024-12-18 | 2026-10-08 |
| Perioperative Fostamatinib With Gemcitabine and Nab-paclitaxel in Resectable Pancreatic Cancer Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel) - Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | University of California, San Diego | 36 | 2024-12-05 | 2026-04-07 |
| Special Drug Use-results Survey for Long-term Use (Fostamatinib) fostamatinib - Chronic Idiopathic Thrombocytopenic Purpura | Recruiting | Kissei Pharmaceutical Co., Ltd. | 149 | 2023-05-29 | 2025-01-03 | |
| Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP Fostamatinib - ITP - Immune Thrombocytopenia, Chronic ITP | Completed | Gruppo Italiano Malattie EMatologiche dell'Adulto | 95 | 2023-05-05 | 2025-04-30 | |
| Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias fostamatinib - Immune Mediated Anemia, Immune Mediated Thrombocytopenia | Phase 2 | Terminated | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-03-10 | 2025-12-05 |
| Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study Fostamatinib - Primary Immune Thrombocytopenia | Completed | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 50 | 2023-03-01 | 2023-10-17 | |
| International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response Fostamatinib, Placebo - COVID-19, SARS-CoV2 Infection | Phase 2 / Phase 3 | Terminated | NEAT ID Foundation | 28 | 2022-10-27 | 2025-05-02 |
| Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis Suppurativa Fostamatinib - Hidradenitis Suppurativa | Phase 2 | Completed | Holdsworth House Medical Practice | 20 | 2021-10-01 | 2023-03-01 |
| Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents Fostamatinib - Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | Phase 1 | Completed | M.D. Anderson Cancer Center | 11 | 2021-08-13 | 2025-02-13 |
| Novel Experimental COVID-19 Therapies Affecting Host Response TXA127, TRV027, Placebo - COVID-19, SARS-CoV-2 Infection | Phase 2 / Phase 3 | Completed | Sean Collins | 1060 | 2021-07-15 | 2025-01-22 |
| Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy Fostamatinib - ITP, Immune Thrombocytopenia | Terminated | Rigel Pharmaceuticals | 16 | 2021-05-18 | 2024-03-15 | |
| Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe Thrombocytopenia Fostamatinib, Ruxolitinib - Myelofibrosis, Thrombocytopenia | Phase 2 | Terminated | Washington University School of Medicine | 3 | 2021-05-03 | 2023-12-15 |
| Double-Blind, Randomized, Placebo-Controlled, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects Fostamatinib, Placebo - Covid19, SARS (Severe Acute Respiratory Syndrome) | Phase 3 | Completed | Rigel Pharmaceuticals | 280 | 2021-03-25 | 2023-08-18 |
| Fostamatinib for Hospitalized Adults With COVID-19 Placebo, fostamatinib - Coronavirus Disease 2019 | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 59 | 2020-10-08 | 2022-03-02 |
| Inflammatory Signal Inhibitors for COVID-19 (MATIS) Ruxolitinib, Fostamatinib, Standard of care - Coronavirus, Covid19 | Phase 1 / Phase 2 | Completed | Imperial College London | 185 | 2020-10-02 | 2025-11-18 |
| A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788 R788, Placebo - Idiopathic Thrombocytopenic Purpura | Phase 3 | Completed | Kissei Pharmaceutical Co., Ltd. | 34 | 2019-12-24 | 2025-08-11 |
Showing 20 of 63. Sign in to see all of them.
Arthritis, Rheumatoid (20) · Purpura, Thrombocytopenic, Idiopathic (11) · COVID-19 (5) · Bronchiolitis Obliterans Syndrome (3) · Coronavirus Infections (3) · Lymphoma (3) · Glomerulonephritis, IGA (2) · Graft vs Host Disease (2) · Pneumonia (2) · Anemia, Sickle Cell (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Colorectal Neoplasms (1) · Head and Neck Neoplasms (1) · Hematologic Neoplasms (1)
AstraZeneca (23) · Rigel Pharmaceuticals (18) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Imperial College London (2) · Kissei Pharmaceutical Co., Ltd. (2) · Stefanie Sarantopoulos, MD, PhD. (2) · Fundación Pública Andaluza para la gestión de la Investigación en Sevilla (1) · Gruppo Italiano Malattie EMatologiche dell'Adulto (1) · Holdsworth House Medical Practice (1) · Inova Health Care Services (1) · M.D. Anderson Cancer Center (1) · NEAT ID Foundation (1) · National Cancer Institute (NCI) (1) · Sean Collins (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (45) · United Kingdom (18) · Germany (13) · Bulgaria (11) · Italy (11) · Canada (10) · Czechia (10) · Poland (9) · Spain (9) · Hungary (8) · Australia (7) · Belgium (7) · France (7) · Mexico (7) · Romania (7)
Neil MacKillop, MD PhD (5) · Mark Layton, MD (4) · Carlos Prendes, MD (2) · Chris O'Brien, MD PhD (2) · Daniel B Magilavy, MD (2) · Jamie Y Hur, D.O. (2) · Jeffrey Skolnik, MD (2) · Thomas Marbury, MD (2) · Amy Zhou, M.D. (1) · Andrew Lowy, MD (1) · Anne-Marie Duliege, M.D. (1) · Anton Pozniak, Prof (1) · Arthur Kavanaugh, M.D. (1) · Bernadette Weidman, RN, MSN, PMP (1)
PMID 33995988, PMID 26519231, PMID 33254235, PMID 19096013, PMID 19965662, PMID 20879879, PMID 25074688, PMID 26032537, PMID 26514315, PMID 29669391, PMID 30177021, PMID 33367731, PMID 33845867, PMID 34124781, PMID 34467402, PMID 34473343, PMID 35179251, PMID 37039791, PMID 37522746, PMID 39625722, PMID 41644167
2008 (1), 2014 (1), 2018 (1)